Optimising mitomycin C activity during intravesical instillation

✍ Scribed by Jauhiainen, K. ;Kangas, L. ;Nieminen, A.-L. ;K�pyl�, H. ;Alfthan, O.

• Book ID: 104686810
• Publisher: Springer
• Year: 1983
• Tongue: English
• Weight: 280 KB
• Volume: 11
• Category: Article
• ISSN: 0300-5623
• DOI: 10.1007/bf00256948

✦ Synopsis

Walker 256 carcinosarcoma was shown to be sensitive to mitomycin C in vitro. In order to make practical recommendations for the clinical intravesical use of mitomycin C, this cell line was used to evaluate the activity of mitomycin C under different conditions. Mitomycin C loses its antitumour activity rapidly at pH's below 6. At higher pH's (up to 10) mitomycin C is stable and suitable for intravesical application. To secure a sufficiently high pH in the bladder during intravesical treatment, phosphate buffer 0.05 M with a pH of 7.4 is recommended. Constituents of urine very little decrease the activity of buffered mitomycin C during a 2 h application. Prednisolone, which has been suggested to prevent the harmful chemical cystitis, has no inhibitory effect on the activity of mitomycin C.